360 related articles for article (PubMed ID: 26017328)
1. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.
Sekijima Y; Tojo K; Morita H; Koyama J; Ikeda S
Amyloid; 2015; 22(2):79-83. PubMed ID: 26017328
[TBL] [Abstract][Full Text] [Related]
2. Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.
Ikram A; Donnelly JP; Sperry BW; Samaras C; Valent J; Hanna M
Amyloid; 2018 Sep; 25(3):197-202. PubMed ID: 30388377
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
4. The use of diflunisal for transthyretin cardiac amyloidosis: a review.
Ibrahim M; Saint Croix GR; Lacy S; Fattouh M; Barillas-Lara MI; Behrooz L; Mechanic O
Heart Fail Rev; 2022 Mar; 27(2):517-524. PubMed ID: 34272629
[TBL] [Abstract][Full Text] [Related]
5. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Sekijima Y
Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis.
Lohrmann G; Pipilas A; Mussinelli R; Gopal DM; Berk JL; Connors LH; Vellanki N; Hellawell J; Siddiqi OK; Fox J; Maurer MS; Ruberg FL
J Card Fail; 2020 Sep; 26(9):753-759. PubMed ID: 31805416
[TBL] [Abstract][Full Text] [Related]
7. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL
Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
9. Diflunisal for ATTR cardiac amyloidosis.
Castaño A; Helmke S; Alvarez J; Delisle S; Maurer MS
Congest Heart Fail; 2012; 18(6):315-9. PubMed ID: 22747647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.
Takahashi R; Ono K; Shibata S; Nakamura K; Komatsu J; Ikeda Y; Ikeda T; Samuraki M; Sakai K; Iwasa K; Kayano D; Yamada M
J Neurol Sci; 2014 Oct; 345(1-2):231-5. PubMed ID: 25060417
[TBL] [Abstract][Full Text] [Related]
11. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
Sekijima Y; Dendle MA; Kelly JW
Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
[TBL] [Abstract][Full Text] [Related]
12. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
13. Correct Diagnosis of Wild-Type Transthyretin-Related Amyloidosis Followed by the Introduction of a Novel Therapy in a Patient With Cardiac Wall Thickening of Unknown Cause.
Sawada N; Nakayama A; Takahashi M; Tanaka M; Morita H; Akazawa H; Komuro I
Int Heart J; 2017 Feb; 58(1):147-150. PubMed ID: 28111409
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid.
Eriksson M; Büttner J; Todorov T; Yumlu S; Schönland S; Hegenbart U; Kristen AV; Dengler T; Lohse P; Helmke B; Schmidt H; Röcken C
Am J Surg Pathol; 2009 Jan; 33(1):58-65. PubMed ID: 18830126
[TBL] [Abstract][Full Text] [Related]
15. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and biochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation.
Huang G; Ueda M; Tasaki M; Yamashita T; Misumi Y; Masuda T; Suenaga G; Inoue Y; Kinoshita Y; Matsumoto S; Mizukami M; Tsuda Y; Nomura T; Obayashi K; Ando Y
Amyloid; 2017 Mar; 24(1):24-29. PubMed ID: 28081656
[TBL] [Abstract][Full Text] [Related]
17. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Tojo K; Sekijima Y; Kelly JW; Ikeda S
Neurosci Res; 2006 Dec; 56(4):441-9. PubMed ID: 17028027
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.
Yokoyama T; Mizuguchi M
Biol Pharm Bull; 2018; 41(7):979-984. PubMed ID: 29962408
[TBL] [Abstract][Full Text] [Related]
19. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Lamb YN; Deeks ED
Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
[TBL] [Abstract][Full Text] [Related]
20. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
Zibert A; Hüsing-Kabar A; Schmidt H
Dtsch Med Wochenschr; 2019 Oct; 144(20):1438-1443. PubMed ID: 31594020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
